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Abstract 
We have traditionally viewed ischemic heart disease in a cardiocentric manner: plaques 
grow in arteries until they block blood flow, causing acute coronary and other ischemic 
syndromes. Recent research provides new insight into the integrative biology of inflammation as 
it contributes to ischemic cardiovascular disease. These results have revealed hitherto 
unsuspected inflammatory signaling networks at work in these disorders that link the brain, 
autonomic nervous system, bone marrow, and spleen to the atherosclerotic plaque and to the 
infarcting myocardium. A burgeoning clinical literature indicates that such inflammatory 
networks—far from a mere laboratory curiosity—operate in our patients and can influence 
aspects of ischemic cardiovascular disease that determine decisively clinical outcomes. These 
new findings enlarge the circle of the traditional “cardiovascular continuum” beyond the heart 
and vessels to include the nervous system, the spleen, and the bone marrow. 
 
<KW>Key words: acute coronary syndromes, myocardial infarction, white blood cells 
 
Abbreviations: 
CCR = CC chemokine receptor 
FdG = fluorodeoxyglucose 
FLT = fluorothymidine 
IFN-γ = interferon gamma 
IL = interleukin 
LDL = low-density lipoprotein 
M-CSF/CSF-1 = macrophage colony stimulating factor 
TGF-β = transforming growth factor beta 
Th1 cells = T lymphocytes  
VEGF = vascular endothelial growth factor 
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Leukocyte functions in atherosclerosis 
Several decades of accumulated experimental and clinical evidence have brought 
inflammation to the fore as a common mechanism that links traditional and emerging risk factors 
to altered behavior of arterial wall cells, and accumulation and activation of leukocytes within 
arterial lesions (Table 1). Moreover, we appreciate increasingly the contribution of inflammation 
and leukocytes to many myocardial diseases (1). Although many gaps remain, our knowledge 
has progressed to the point where we can begin to gain insight into the integrative biology of 
inflammation as it contributes to ischemic cardiovascular disease. This review summarizes the 
experimental evidence that has disclosed a hitherto unsuspected inflammatory signaling network 
at work in these disorders that links the brain, bone marrow, spleen, the atherosclerotic plaque, 
and the infarcting myocardium. It will also discuss the burgeoning clinical literature suggesting 
that such inflammatory networks—far from a mere laboratory curiosity—actually operate in our 
patients and can influence aspects of ischemic cardiovascular disease that determine decisively 
clinical outcomes. 
The study of inflammation biology in cardiovascular disease has focused a great deal on 
protein mediators, such as cytokines and chemokines, or on small molecules, such as the 
prostaglandins and reactive oxygen or nitrogen species. This review will deal in greater detail 
with the cellular protagonists in inflammation: leukocytes, the bulwark of host defenses and the 
sources for many of the protein and lipid mediators implicated in cardiovascular diseases. These 
cellular citizens not only orchestrate innate immunity, but serve as messengers that link organ 
systems implicated in novel inflammatory networks revealed in recent investigations. 
Our view of the pathogenesis of atherosclerosis has shifted radically in recent decades. 
Previously viewed as a lipid storage disease, we now recognize that inflammation drives much of 
4 
the atherogenic process and mechanisms of clinical complications of this disease. Although lipid 
risk factors (notably low-density lipoprotein [LDL]) likely play a permissive role in human 
atherogenesis, many other diseases and their associated triggers to inflammation may aggravate 
atherosclerotic risk (Table 1). 
Pioneering pathologists of the 19th century recognized the foam cell as a hallmark of 
atherosclerotic lesions (2,3). Studies of increasing rigor identified these cells as lipid-laden 
macrophages. Smooth muscle cells may also accumulate lipid in atheromata. Recent work has 
suggested fuzzy borders between macrophages and smooth muscle cells, particularly in 
experimental lesions in mice (4,5). Yet, most agree that the majority of foam cells in plaques 
derive from mononuclear phagocytes. Many prior reviews have described how blood monocytes, 
captured by adhesion molecules on the surface of endothelial cells stimulated by 
proinflammatory cytokines, enter the arterial wall, beckoned by chemokines (6,7). Scavenger 
receptors regulated, in part, by inflammatory mediators expressed on the surface of plaque 
macrophages, permit them to accumulate cholesterol, packing their cytoplasm with lipid droplets 
that yield the characteristic foamy appearance of the plaque macrophage. 
Descriptions of leukocyte recruitment to nascent plaques have generally considered 
monocytes as a homogenous population. We now appreciate a much more interesting and 
complex picture of the population of mononuclear phagocytes in atherosclerotic plaques. We 
postulated the heterogeneity of mononuclear phagocytes in the atherosclerotic plaque in the 
1990s on the basis of varied expression of scavenger receptors and markers of inflammatory 
activation, such as Class II major histocompatibility antigens in plaque macrophages (8). Only 
more recently have we come to appreciate the role of differential accumulation of various 
macrophage subsets to the artery wall as one mechanism of this heterogeneity (9,10). Moreover, 
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even before the initiation of atherogenesis, the artery wall contains a population of “resident” 
mononuclear phagocytes, including dendritic cells (11,12). 
Much of our recent knowledge of the generation of heterogeneity of mononuclear 
phagocytes during atherogenesis derives from studies on genetically modified mice. 
Observations in humans have begun to support the relevance of the concepts that have emerged 
from the study of experimental atheromata to humans. During hypercholesterolemia in mice, a 
proinflammatory subset of monocytes, marked by high levels of the surface protein Ly6c, 
accumulate in the peripheral blood. Nascent atherosclerotic plaques selectively recruit these 
proinflammatory monocytes, primarily mediated by macrophage chemoattractant protein-1 
(MCP-1) interacting with its receptor, CC chemokine receptor (CCR)-2 (Figure 1, left side). 
These cells take up residence in the artery wall where they can elaborate proinflammatory 
mediators that amplify and sustain inflammation within the early plaque. Mononuclear 
phagocytes within plaques can replicate in situ. 
Whereas the accumulation of these cells in early plaques appears to result from 
heightened recruitment, their replication predominates as a mechanism underlying their 
increased number in established plaques (13). The replication of mononuclear phagocytes within 
the atheroma depends on hematopoietic growth factors, including macrophage colony-
stimulating factor (M-CSF/CSF-1) (14). We localized M-CSF and granulocyte-macrophage 
colony-stimulating factor (GM-CSF) to human and experimental atherosclerotic plaques (15-17). 
We also found that M-CSF stimulated scavenger receptor expression on these cells and promoted 
their maturation into macrophages (15). 
Once taking up residence and multiplying within the artery wall, mononuclear 
phagocytes have several fates. Retention factors can retard their transit in the plaque and 
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discourage their egress. These retention factors include neural guidance factors, such as netrin-1 
and the leukocyte adhesion molecule vascular cell adhesion molecule-1 (VCAM-1) (18-21). 
Mononuclear phagocytes can eventually leave the plaque. Although the mechanisms remain 
controversial, lymph channels provide one apparent portal for egress of these cells (22,23). Some 
experimental evidence suggests that elevating concentrations of high-density lipoprotein (HDL) 
or lowering the concentration of low-density lipoprotein (LDL) can promote the efflux of 
monocytes from plaques (23). In mice, augmented expression of CCR-7 on leukocytes and 
reduced retention mediators appear to favor monocyte emigration under conditions of lipid 
lowering (23,24). 
Death of mononuclear phagocytes also occurs in atheromata (25). These cells can perish 
due to “accidental cell death” (oncosis, often erroneously referred to as “necrosis”) (26). They 
also often die by apoptosis (25,27). Dying macrophages can release microparticles that contain 
the procoagulant tissue factor. They also elaborate proinflammatory cytokines, such as 
interleukin-1-alpha (IL-1α). Dying macrophages might also provide a nidus for 
microcalcifications. Such calcific foci may lead to biomechanical inhomogeneities postulated to 
favor plaque rupture (28).  
Other mononuclear phagocytes usually rapidly engulf dead or dying cells and ferry them 
from the plaque, a process known as efferocytosis. We noted in the 1990s that, on the basis of 
arithmetic considerations, clearance of dead cells from plaques appeared impaired (25). Tabas et 
al. popularized the concept of defective efferocytosis of phagocytes within atheromatous plaques 
(5,29). They studied the underlying mechanisms that regulate efferocytosis within the plaque, 
which likely contribute to the formation of a lipid-rich “necrotic” core (30). 
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Some of the monocyte/macrophages within plaques assume a set of functions that may 
mute inflammation and promote tissue repair. These cells express low levels of Ly6c and 
elaborate IL-10, vascular endothelial growth factor (VEGF), a promoter of angiogenesis, and 
transforming growth factor beta (TGF-β), a stimulator of fibrosis (Figure 2) (31). 
The atheroma harbors other leukocytes, in addition to mononuclear phagocytes. T 
lymphocytes, although less numerous, likely have important regulatory functions instructing 
macrophages (6,32,33). These adaptive immune cells also display considerable functional 
heterogeneity. Certain T lymphocytes (Th1 cells) primarily secrete proinflammatory cytokines, 
such as interferon gamma (IFN-γ), that promote atherosclerosis and activate inflammatory 
functions of macrophages. A specialized subset of adaptive immune cells, innate response 
activator (IRA) B cells, can promote Th1 polarization (34). Another T lymphocyte subclass 
known as Th2 lymphocytes can mute inflammation by secreting anti-inflammatory cytokines, 
such as IL-10. A distinct T cell subset, regulatory T cells (Treg), can suppress inflammation and 
promote fibrogenesis by elaborating TGF-β. Controversy surrounds the role in atherogenesis of 
another T cell subtype, Th17, generally considered proinflammatory. 
B lymphocytes may also modulate atherogenesis (34,35). Natural antibodies secreted by 
B1 lymphocytes appear to protect against atherosclerosis. Many of these antibodies recognize 
oxidized lipoproteins thought to accumulate in atheromata and associate with dying cells. In 
contrast, B2 lymphocytes appear to aggravate atherosclerosis, for example, by producing B cell 
activating factor (BAFF) (36,37). Other leukocyte classes implicated in atherogenesis include 
mast cells, a cell type that localizes in the normal arterial adventitia (38-40). Cytokines produced 
by mast cells, such as IL-6 and IFN-γ may aggravate atherogenesis (39). The role of mast cells in 
human atherogenesis requires further study (41). 
8 
The picture that emerges from contemporary studies of leukocytes in atherogenesis 
highlights a tug of war between proinflammatory subsets of each leukocyte class and their less 
inflammatory or “reparative” counterparts. This constant competition can contribute to the 
chronicity of atherosclerotic plaques, a process that progresses over many decades. Not only 
does the balance between these countervailing forces vary in time during the life of the plaque, 
but also in space. Different plaques in the same circulatory bed or in the same person may exhibit 
different states of inflammatory activation, in part attributable to distinct balances between pro- 
and anti-inflammatory subsets of leukocytes. Recent reviews have considered the manner in 
which mononuclear phagocytes and crosstalk with adaptive immune cells may exert functions 
that precipitate lesion complications, such as plaque rupture and thrombosis (42). 
Leukocyte functions in Acute Myocardial Infarction 
Acute coronary syndromes bring patients with atherosclerosis to the cardiologist’s 
attention most dramatically. Leukocytes contribute decisively to acute ischemic injury of the 
myocardium. Pathologists have long recognized the participation of successive waves of 
different leukocyte classes in the process of myocardial infarction (Figure 2) (43). An initial 
wave of acute inflammatory cells, the polymorphonuclear leukocytes, arrives within minutes and 
dominates the leukocyte population in the infarcting myocardium during the first day or so 
following the onset of ischemia. Mononuclear phagocytes also begin to accumulate within the 
first hours of ischemia, and predominate by days 3 through 5 in the leukocytes present in 
infarcting myocardium. 
Recent experimental work has resolved the population of mononuclear phagocytes in the 
plaque into an initial proinflammatory subset, followed some days later by a second wave of less 
inflammatory monocytes (Figure 2) (44). The initial proinflammatory population of monocytes 
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arises by recruitment from the bone marrow and from a preformed pool located in the spleen in 
mice (45). This recruitment depends in part on angiotensin II, an observation that may underlie 
the salutary effect of interruption of angiotensin action on remodeling of the infarcting 
myocardium (46). The pivot to less inflammatory phagocytes in the latter phase appears to result 
from a shift in the programming of the mononuclear cells, rather than recruitment of less 
inflammatory monocytes. A transcription factor, Nr4A1, modulates gene expression towards a 
reparative set of functions, although this transition doubtless involves other regulatory 
mechanisms (47). 
The proinflammatory monocytes comprise a “demolition crew” with highly active 
phagocytosis, elaboration of proteolytic enzymes, and proinflammatory cytokines, that 
participate in clearing of the debris of dead and dying cells in the infarct and paving the way for 
reconstruction (Central Illustration). The reparative monocytes elaborate angiogenic factors, 
such as VEGF and the fibrogenic mediator TGF-β, which promote formation of granulation 
tissue, a provisional matrix, the scaffold for eventual repair of the infarcted myocardium and 
replacement with fibrotic scar. 
The sequencing of leukocytes in the atheroma has profound functional consequences for 
healing of the infarct (48). Under hypercholesterolemic conditions, an excess of proinflammatory 
monocytes in blood impairs the healing of infarcts (49). Interference with inflammatory 
functions of monocytes by therapeutic small interfering ribonucleic acid (siRNA) silencing can 
improve the function of the infarcted ventricle. Interference with CCR2 promotes repair of the 
infarcted ventricle and yields improvement in ventricle function following coronary ligation (50). 
Silencing of the transcription factor IRF-5 also reprograms the mononuclear phagocytes in the 
infarct and improves healing (51). 
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The preformed pool in the spleen of proinflammatory monocytes undergoes 
replenishment due to “emergency” extramedullary hematopoiesis (Central Illustration) (52). 
Recruitment of precursor cells for myelocytic lineage leukocytes furnishes the precursors of 
leukocytes that multiply in the spleen. The proinflammatory monocytes in the spleen lie in wait 
for mobilization to sites of tissue injury, such the acutely ischemic myocardium. 
These various observations have opened up new vistas into the mechanisms by which 
inflammatory cells can “clean up” damage of the ischemically damaged myocardium and 
modulate the healing process. Healthy healing of the ventricle can forestall adverse remodeling 
of the infarcted left ventricle and preserve ventricular function. These insights provide the 
opportunity of tuning the function of mononuclear phagocytes during myocardial infarction in a 
manner that can lessen the likelihood of ischemic cardiomyopathy as a critically important long-
term consequence of an ischemic insult to the myocardium. 
Integrative Pathophysiology of Inflammation in Ischemic Heart Disease 
The foregoing sections have emphasized the mechanisms of local inflammatory 
responses mediated by leukocyte subclasses in the atherosclerotic plaque itself and in the 
myocardium. Recent work has also shed new light on crosstalk between inflammation in various 
regions and systemic inflammatory responses. In the early days of exploring the molecular bases 
of inflammatory signaling in atherosclerosis, we proposed the hypothesis that systemic 
inflammation could elicit an “echo” in the prepared soil of the atherosclerotic plaque. Soon after 
its purification and cloning, we found that the prototypical proinflammatory cytokine, IL-1, 
could be induced in the artery wall by systemic administration of Gram-negative bacterial 
endotoxin (lipopolysaccharide) (Figure 3A) (53). In the late 1980s, we chose this stimulus as a 
powerful proinflammatory trigger for activation of inflammatory functions. We further found 
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that rabbit arteries affected by atherosclerosis displayed an accentuated response to intravenous 
endotoxin, as gauged by a substantial overproduction of IL-1 isoforms (53). Indeed, arteries with 
greater degrees of atherosclerosis showed increasing amounts of proinflammatory cytokine 
expression (Figure 3B) (54). 
At the time, we considered bacterial endotoxin injection an experimental artifice that we 
employed to explore the hypothesis that a systemic inflammatory stimulus could evoke a local 
inflammatory response. Yet, with greater appreciation of the importance of the intestinal 
microbiome and potential defects in the barrier function of the intestinal epithelium, we now 
recognize that low-level leakage of bacterial products may pertain to human pathophysiology 
much more than we appreciated when we performed these early experiments (Table 1) (55). 
When we considered the mechanisms by which infectious agents might promote atherogenesis, 
we hypothesized that, beyond direct infection within the atheroma, local responses to products of 
microbial invaders could augment local inflammation of the plaque, another instance of an 
“echo” phenomenon linking systemic inflammation to enhanced local responses at the level of 
the atherosclerotic lesion (56). Beyond infectious stimuli for leukocyte activation in the context 
of cardiovascular disease, a variety of autoimmune and autoinflammatory diseases likely trigger 
innate immune activation (Table 1). Indeed, patients with rheumatoid arthritis, systemic lupus 
erythematosus, and other autoimmune diseases have elevated cardiovascular risk and likely 
accelerated atherogenesis, as recently reviewed (57). 
Recent work has considerably expanded this notion by exploring the hypothesis that 
acute local inflammation in the myocardium could augment local inflammation in atherosclerotic 
plaques. Indeed, after coronary artery ligation, atherosclerotic lesions in mice show augmented 
protease activity (58). Thinning of the fibrous cap and increase in the lipid core of pre-existing 
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atherosclerotic plaques also follows coronary ligation. These features of plaques associate with a 
greater propensity to rupture and provoke thrombotic events. These experimental observations 
may explain, in part, the high rate of early recurrence of ischemic events in patients following an 
ACS. 
An increase in recruitment of leukocytes to pre-existing atherosclerotic plaque occurs 
post-coronary ligation in mice. The augmented trafficking of leukocytes to the plaque following 
acute myocardial injury depends on recruitment of progenitor cells from the bone marrow, a 
precursor to extramedullary hematopoiesis and ongoing leukocyte accumulation with the 
atherosclerotic lesion itself. Acute myocardial injury evokes a CCR2-dependent mobilization of 
precursor stem cells from the bone marrow of mice (59). IL-1β participates in the augmented 
leukopoiesis following experimental myocardial infarction (60). The activation of bone marrow 
progenitor cells depends on β3-adrenergic stimulation, linking the sympathetic nervous system to 
the systemic and local inflammatory response in the plaque following myocardial infarction 
(Central Illustration) (58). The pain and stress of the acute infarction promote local 
catecholamine synthesis in the bone marrow, as well as the likely systemic release of β3-
adrenergic stimulants. These observations support the operation of critical links between pain 
perception and stress in the central nervous system, adrenergic signaling through the sympathetic 
nervous system, release of progenitor cells and leukocytes from the bone marrow, and their 
trafficking to sites of extramedullary hematopoiesis or local inflammation, respectively (Central 
Illustration). These observations provide a mechanistic explanation for the oft-invoked link 
between mental stress, a hyperadrenergic state, and the complications of atherosclerosis. Beyond 
the stress due to myocardial infarction, other forms of chronic mental stress can activate these 
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pathways that accentuate local inflammation. Mice exposed to chronic psychosocial stress show 
similar activation of myeloid progenitor cells and heightened inflammation in the plaque (61). 
Sites of tissue injury and ischemic damage beyond the myocardium can elicit an “echo” 
at the level of the atherosclerotic plaque and unleash a remote inflammatory response. For 
example, cerebral ischemia-reperfusion injury, produced in mice by transient middle cerebral 
artery occlusion, can activate both medullary and splenic myelopoiesis, and augment the 
leukocyte number and population of proinflammatory Ly6Chigh monocytes in atheromata (58,62). 
Clinical Translation of Recent Advances in the Inflammation Biology of Atherosclerosis 
and Myocardial Infarction 
Astute clinical observers have long noted that fever and leukocytosis, cardinal signs of 
inflammation, accompany acute myocardial infarction. Samuel A. Levine, a pioneer of 
contemporary cardiology, stated, “the extent of fever and leukocytosis probably depends on the 
amount of infarcted cardiac tissue involved.” (63). In 1929, he further stated, “infarcted 
tissue…probably liberates toxic products that produce leukocytosis and fever…The leukocyte 
count is apt to run hand in hand with the fever…The presence of a leukocytosis is one of the 
most constant findings in coronary thrombosis.” Today we have a much better mechanistic 
understanding of the pathophysiological mechanisms that produce fever and leukocytosis. 
Release of IL-1β from proinflammatory mononuclear phagocytes recruited to the infarct 
furnishes one of the “toxic products” hypothesized by Levine. Dying leukocytes release IL-1α, 
the other isoform of IL-1. IL-1, previously known as an “endogenous pyrogen,” provides a major 
stimulus for fever and can augment the production of hematopoietic growth factors that stimulate 
leukopoiesis, both in the bone marrow and at extramedullary sites (60). 
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Epidemiological observational studies have long shown greater risk of coronary events in 
people with higher circulating leukocyte counts at baseline. Increasing clinical data support the 
importance of mononuclear phagocyte heterogeneity in ischemic heart disease and 
atherosclerosis. Subjects followed in the Malmö cohort who had the highest tertile of CD14++ 
CD16– monocytes had the lowest event-free survival during a 17-year follow-up period (64).  
Other studies have shown relationships between metrics of atherosclerosis and risk of 
cardiovascular events with the presence of circulating proinflammatory monocytes (65,66). 
Supporting the involvement of adrenergic signaling in leukocyte biology in ischemic heart 
disease, patients undergoing ACS who were nonrandomly allocated to beta-blocker use before 
the ACS had significantly lower total leukocyte and monocyte counts than those who had never 
used beta-blockers (58). Autopsy studies in subjects who succumbed during acute myocardial 
infarction show an increased number of proliferating splenic myeloid progenitor cells in their 
parenchyma compared with spleens of people dying noncardiac deaths (58). 
Recent imaging studies underscore the clinical translation of the “splenocardiac” axis 
revealed by mouse experiments. Patients in the throes of an ACS show increased 18F-
fluorodeoxyglucose (18F-FdG) uptake in the bone marrow and spleen compared with those 
having 18F-FdG-positron emission scans in other clinical circumstances (67). The increased 
metabolic activity in the spleens of ACS patients, as evidenced by augmented 18F-FdG uptake, 
correlates with clinical outcomes (Figure 4) (67). Moreover, in medical residents rotating 
between intensive care unit duty and time off, psychological stress (as measured by formal 
psychometric testing) increases during call periods in conjunction with an increase in peripheral 
leukocytosis (61). These clinical observations endorse the translatability of recent findings 
regarding links between stress and local and systemic inflammation in ischemic heart disease. 
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Emerging imaging modalities promise to foster further translational extension of 
experimental work on leukocytes and inflammation biology in cardiovascular disease. A variety 
of molecular imaging approaches including near infrared fluorescence, magnetic resonance, 
computed tomographic, ultrasound, and radionuclide targeted probes have undergone preclinical 
validation, as recently reviewed (68-74). Despite substantial barriers to translation to humans, 
initial clinical studies imaging leukocyte functions beyond glucose transport provide a proof of 
principle that support the continued development of molecular imaging tools to study 
inflammation. A recent study used 18F-fluorothymidine (18F-FLT) as a probe to visualize cellular 
proliferation in experimental and human atherosclerosis (75). This approach permitted 
visualization of proliferation of macrophages in aortic lesions and of leukocyte progenitors in the 
spleen and bone marrow in mice. This proliferation marker also produced signals in human 
carotid artery and aortic atherosclerotic lesions, consistent with visualizing leukocyte replication 
noninvasively (Figure 5). Thus, we look forward to continued translation to human patients of 
recent advances in leukocyte involvement in cardiovascular diseases that have emerged from 
experimental studies. Although molecular imaging will not likely prove clinically or cost-
effective for routine screening, it promises to provide a new pathway for clinical research, and 
may prove useful for developing and evaluating normal therapies that target inflammation and 
leukocyte functions in cardiovascular diseases. 
Conclusion and Clinical Consequences 
The traditional “Cardiovascular Continuum” formulated by Dzau and Braunwald focused 
on the cycle that links arteries and the heart (76). The recent research recounted here has 
enlarged the circle of this continuum beyond the myocardium and blood vessels to embrace the 
nervous system, the spleen, and the bone marrow (Central Illustration). 
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Reductionist research conducted in experimental laboratories over the last decades has 
opened new windows into truly integrative pathophysiology. Study of fundamental inflammation 
biology has revealed these heretofore unsuspected mechanistic links between a variety of organ 
systems intertwined to coordinate the organism’s response to stress and injury. The multiple 
inflammatory mediators, leukocyte subclasses, and their interplay provide a panoply of novel 
potential targets for fine-tuning the inflammatory response during acute myocardial infarction 
and the more chronic smoldering inflammation underway in the atherosclerotic plaque. 
The results of this recent research have uncovered new mechanisms by which proven 
pharmacological interventions may ameliorate the consequences of acute myocardial infarction, 
for example, β-adrenergic blocking agents and angiotensin-converting enzyme inhibitors. These 
results offer perspectives on how tipping the balance between proinflammatory leukocytes and 
their reparative counterparts might augment healthy healing of the infarcted myocardium and 
quell the echo of inflammation in the plaque in response to acute insults, such as myocardial 
infarction. Animal experiments have furnished proof of principle of these concepts in laboratory 
studies. These laboratory observations pave the way for clinical studies that aim to alter 
inflammatory responses mediated by leukocyte subsets to improve patient outcomes following 
ACS and forestall the development of chronic ischemic cardiomyopathy, a challenging and 
growing burden in the contemporary era of cardiology and a major contributor to morbidity and 
strain on the health care system. 
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FIGURE LEGENDS 
Central Illustration. Leukocytes Link Local and Systemic Inflammation in Ischemic 
Cardiovascular Disease: The integrative pathophysiology of inflammation in ischemic 
heart disease. 
The stress of acute myocardial infarction produces an “echo” in atherosclerotic plaques. Acute 
myocardial infarction causes pain and anxiety that triggers sympathetic outflow from the central 
nervous system. β-3-adrenergic stimulation mobilizes leukocyte progenitors from their bone 
marrow niche. These progenitor cells can migrate to the spleen, where they can multiply in 
response to hematopoietic growth factors. The proinflammatory monocytes then leave the spleen 
and enter the atherosclerotic plaque, where they promote inflammation that can render a plaque 
more likely to provoke thrombosis and hence acute myocardial infarction. IL = interleukin. 
Figure 1. Heterogeneity of Mononuclear Phagocytes in the Atheroma 
In early atherosclerotic plaques (shown on the left-hand side of the diagram), proinflammatory 
leukocytes, characterized by high levels of Ly6c and the chemokine receptor CCR2, 
preferentially adhere to the activated endothelial monolayer overlying the early plaque. The 
adherent leukocytes enter the intima by diapedesis. Accumulation of mononuclear phagocytes in 
the early atherosclerotic plaque occurs primarily by recruitment from blood. In the advancing 
atheroma (right-hand portion of the diagram), monocyte macrophage replication occurs in 
response to hematopoietic growth factors, some of which may arise from a specialized set of B 
lymphocytes known as immune response activator B cells (34). The mitotic figures indicate 
cellular replication. Mononuclear phagocytes resident in the intima ultimately will accumulate 
cholesteryl ester, forming foam cells, the hallmark of the atherosclerotic lesion. CCR = CC 
chemokine receptor.  
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Figure 2. Temporal Sequence and Functions of Leukocytes Localizing in the Infarcting 
Myocardium 
Granulocytes arrive in the ischemic area within hours of the onset of infarction. The 
granulocytes, “first responders” to ischemic injury, elaborate pro-oxidants, proteinases, 
cytokines, and lipid mediators among other substances that amplify the acute inflammatory 
response. Examples of the mediators are shown in parentheses. In the second and third day 
following onset of myocardial ischemia, proinflammatory monocytes bearing high levels of the 
marker Ly6c and the chemokine receptor CCR2 accumulate in the infarcting tissue. These cells 
perform cleanup functions by secreting proteinases that can digest debris from dead or dying 
cells. They can phagocytose the debris and engulf dead cells by efferocytosis. These 
“demolition” functions can help pave the way for tissue repair. From days 4 through 7, 
monocytes, macrophages that exhibit reparative functions, assume predominance. In mice, these 
cells arise from the proinflammatory monocytes in response to transcriptional control by Nr4a1. 
These reparative monocytes elaborate TGF-β, which stimulates the collagen synthesis necessary 
for scar formation and healthy healing of the ischemic area. Angiogenic mediators, such as 
VEGF, stimulate microvessels characteristic of granulation tissue in the healing myocardium. 
These reparative monocytes can also elaborate anti-inflammatory cytokines, such as IL-10, that 
can quell the inflammatory response after clearance of the acutely injured cells and foster 
formation of a fibrous scar. IL = interleukin; MMP = matrix metalloproteinase; TGF = 
transforming growth factor; VEGF = vascular endothelial growth factor. 
Figure 3. An “Echo” of Systemic Inflammation in the Atheroma 
(A)The left-hand panel shows northern blots for IL-1α-(top) and IL-1β (bottom) in the aortas of 
nonatherosclerotic and atherosclerotic animals without or with intravenous administration of 
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Gram-negative bacterial endotoxin (lipopolysaccharide [LPS]). Note the striking increase in 
mRNA encoding both isoforms of IL-1 in the atherosclerotic artery following LPS 
administration. (B) mRNA concentrations measured by reverse transcriptase-polymerase chain 
reaction in extracts of the aortas of rabbits that consumed a chow diet or graded increases in 
concentrations of dietary cholesterol from 0.1% to 0.9 %. Note the marked increase in IL-1β 
mRNA concentrations in the animals treated with intravenous endotoxin for 1 h (gray bars) 
versus control. These early experiments illustrate the principle that the resting atheroma can 
undergo inflammatory activation in response to a systemic proinflammatory stimulus. LPS = 
lipopolysaccharide; mRNA = messenger ribonucleic acid; RNA = ribonucleic acid. Other 
abbreviations as in Figure 2. 
Figure 4. Activation of Glucose Uptake in the Arterial Wall, Spleen, and Bone Marrow in 
Patients With Acute Coronary Syndromes  
18F-fluorodeoxyglucose (18F-FdG) uptake increased significantly in the arterial wall (aorta), bone 
marrow, and spleen in patients with acute coronary syndrome (ACS) versus control subjects. 
Reprinted from Emami et al. (67). 
Figure 5. Regions of the Atherosclerotic Human Aorta Accumulate Imaging Reporters of 
Glucose Uptake (18F-FdG) and Cell Proliferation (18F-FLT) 
(A) Sagittal image disclosing extensive calcification in a human aorta and carotid artery 
(arrows). (B) 18F-fluorodeoxyglucose (18F-FdG) and (C) 18F-fluorothymidine (18F-FLT) images 
show accumulation of these positron emission tomography (PET) tracers in the aortic arch 
(arrows). Reprinted from Ye et al. (75). 
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Table 1. Some Triggers and Associated Diseases Implicated in Activating Leukocytes in 
Cardiovascular Diseases 
 
Low-density lipoprotein (LDL) 
Triglyceride-rich lipoproteins (TGRL) 
 Apolipoprotein C3 
Angiotensin II 
Chronic autoimmune conditions 
Rheumatoid arthritis, systemic lupus erythematosus, inflammatory bowel disease, 
psoriasis, etc. 
Chronic autoinflammatory conditions 
 For example, gout, familial Mediterranean fever 
Chronic infections 
 For example, periodontitis, bronchitis, nonhealing skin ulcers 
Microbial agents and their products (e.g., from gut microbiota) 
Pathogen–associated molecular patterns (PAMPs), for example, endotoxins, heat 
shock proteins 
Visceral obesity and ectopic adipose tissue 
Diabetes 
Major tissue injury 
 For example, myocardial infarction, stroke, trauma  
Dying cell products 
 Oncosis, apoptosis, pyroptosis 
Sympathetic nervous stimulation 
Chronic and acute mental stress 
 
 
 
 
 
 
